This is the authors' abstract. We don't add key points for this paper.
We read with interest the recent article by Khalili et al.1 They presented an important message regarding the cost of healthcare in the diagnosis and management of chronic disease. Few studies truly consider the total cost of medical care when defining the type and frequency of interactions with patients. One notable example at a national level was the development of the NICE guidelines in the UK.2 Apart from the analysis of key, high cost compounds (e.g., biologics), these costs are all too often overlooked, potentially leading to reduced capacity in the healthcare system due to financial constraints. Furthermore, their productivity costs (one of the two main components of their cost estimates) typically receive very little attention, although they significantly impact both the individual and society with economic impacts of absenteeism and presenteeism estimated at 1% of GDP.3 We believe, however, that the cost estimates published in this paper under-represent the true cost to the individual and to society. One area not captured by the authors was the volume and impact of community pathology testing undertaken by the patients. This is of particular relevance for patients with inflammatory bowel disease (IBD) and other auto-inflammatory disorders given the frequent and increasing use of immunomodulatory and biologic therapies in these populations. To assess the financial impact, we acquired historical pathology testing data on 2000 patients with IBD managed as outpatients at the Royal Brisbane and Women's Hospital, Queensland, Australia. We assessed the number and cost of tests performed per individual at the year of diagnosis and then ongoing for the next 10 years following diagnosis based on tests performed by the two major private pathology laboratories in Queensland. In the initial 3 months post-diagnosis, the cost of pathology testing was approximately $1350 and $1197 USD per patient diagnosed with CD and UC, respectively. At 18 months post-diagnosis, these quarterly costs reduced to $929 and $897 for CD and UC. Decreases in costs between 18 months and 5 years were minimal, suggesting that routine long-term pathology testing was maintained over a long time for these patients. (Figure 1). Future studies should consider all areas of potential cost, including those charged by pathology services where possible.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lord et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: